Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: Differences in mode of cyclooxygenase inhibition

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 1, 2013, Pages 85-94

  Kodela, Ravinder ^a   Chattopadhyay, Mitali ^a   Goswami, Satindra ^a   Gan, Zong Yuan ^a   Rao, Praveen P N ^b   Nia, Kamran V ^a   Velázquez Martínez, Carlos A ^c   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETOXYBENZOIC; 3 ACETOXYBENZOIC; 4 ACETOXYBENZOIC; ACETYLSALICYLIC ACID; MALONALDEHYDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOMER; LIPID PEROXIDATION; MALE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH ULCER; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; CELL CYCLE; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; ISOMERISM; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; STOMACH ULCER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875427825     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201970     Document Type: Article

References (38)

1. Aalykke C and Lauritsen K (2001) Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 15:705-722.
2. Awtry EH and Loscalzo J (2000) Aspirin. Circulation 101:1206-1218.
3. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, and Cerhan JR (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126:149-155.
4. Best R, Lewis DA, and Nasser N (1984) The anti-ulcerogenic activity of the unripe plantain banana (Musa species). Br J Pharmacol 82:107-116.
5. Chan AT, Ogino S, and Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142.
6. Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdellatif KR, Keefer LK, and Kashfi K (2010) Comparison between 3-nitrooxyphenyl acetylsalicylate (NOASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2- diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs. J Pharmacol Exp Ther 335:443-450.
7. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, and Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256-266.
8. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, and Tappenden P (2010) Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 14:1-206.
9. Fiorucci S and Del Soldato P (2003) NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 35 (Suppl 2):S9-S19.
10. Gao F, Liao C, Liu L, Tan A, Cao Y, and Mo Z (2009) The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Colorectal Dis 11:893-901.
11. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, and Baron JA (2009) Nonsteroidal antiinflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst 101: 267-276.
12. Grösch S, Maier TJ, Schiffmann S, and Geisslinger G (2006) Cyclooxygenase-2 (COX- 2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747.
13. Harris RE (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42:93-126.
14. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, and Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467-1472.
15. Kashfi K and Rigas B (2005a) Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 33:724-727.
16. Kashfi K and Rigas B (2005b) Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70:969-986.
17. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, and Rigas B (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue typeindependent effect. J Pharmacol Exp Ther 303:1273-1282.
18. Lichtenberger LM, Romero JJ, and Dial EJ (2007) Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 150:913-919.
19. Ligumsky M, Grossman MI, and Kauffman GL, Jr (1982) Endogenous gastric mucosal prostaglandins: their role in mucosal integrity. Am J Physiol 242:G337-G341.
20. Liu JF, Jamieson GG, Wu TC, Zhu GJ, and Drew PA (2009) A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol 16:1397-1402.
21. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, and Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232.
22. Pandeya N, Webb PM, Sadeghi S, Green AC, and Whiteman DC; Australian Cancer Study (2010) Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut 59: 31-38.
23. Perini R, Fiorucci S, and Wallace JL (2004) Mechanisms of nonsteroidal antiinflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can J Gastroenterol 18: 229-236.
24. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, and Rigas B (1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258:215-223.
25. Rouzer CA and Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res 50 (Suppl):S29-S34.
26. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C, Schou M, and Curnow KM (2006) Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 185:501-506.
27. Scheiman JM and Fendrick AM (2007) Summing the risk of NSAID therapy. Lancet 369:1580-1581.
28. Serhan CN and Chiang N (2002) Lipid-derived mediators in endogenous antiinflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. Scientific World J 2:169-204.
29. Sheng H, Shao J, Morrow JD, Beauchamp RD, and DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362-366.
30. Singh G and Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 56:18-24.
31. Smith WL, DeWitt DL, and Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182.
32. Tenenbaum J (1999) The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 13:119-122.
33. Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, and Schwartz AG (2008) Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 17:148-157.
34. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
35. Vane JR, Bakhle YS, and Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120.
36. Wong BC, Jiang XH, Lin MC, Tu SP, Cui JT, Jiang SH, Wong WM, Yuen MF, Lam SK, and Kung HF (2004) Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gastroenterology 126:136-147.
37. Yasuda O, Takemura Y, Kawamoto H, and Rakugi H (2008) Aspirin: recent developments. Cell Mol Life Sci 65:354-358.
38. Yeomans ND, Hawkey CJ, Brailsford W, and Naesdal J (2009) Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal antiinflammatory drugs. Curr Med Res Opin 25:2785-2793.